Lunai Bioworks IncLNAI
Price$1.38

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $20.9K+100.0% YoYTTM through 31 Mar 2026
Net Income -$2.6MTTM through 31 Mar 2026
Free Cash Flow -$3.4MTTM through 31 Mar 2026

Margins

Current
Operating Margin-6,815.3%
Net Margin-12,278.6%

Returns

26.9%ROE
-26.1%ROA

Balance Sheet Health

Debt / Equity-0.09x
Net Debt-$1.7Mnet cash position
Cash & Equivalents$3.2M

Quality Metrics

FCF Margin-16,460.6%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Renovaro Biosciences
View details

Completed pre-IND/IND-enabling work for an allogeneic vaccine platform.

BioSymetrics
View details

Advanced multimodal AI capabilities (Contingent AI, Phenograph) and zebrafish screening.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.